


## PHARMACEUTICAL 2021

## MusclePharm Corp Rank 153 of 409







## PHARMACEUTICAL 2021

## MusclePharm Corp Rank 153 of 409



The relative strengths and weaknesses of MusclePharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MusclePharm Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 938% points. The greatest weakness of MusclePharm Corp is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 659% points.

The company's Economic Capital Ratio, given in the ranking table, is -55%, being 299% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	11,864
Cost of Goods Sold	44,831
Intangible Assets	356
Liabilities, Current	32,007
Liabilities, Non-Current	343
Other Assets	769
Other Compr. Net Income	0
Other Expenses	10,877
Other Liabilities	5,071
Other Net Income	1,592
Property and Equipment	13
Research and Development	0
Revenues	64,440
Selling, General and Administrative Expense	7,139

Output Variable	Value in 1000 USD
Assets	13,002
Liabilities	37,421
Expenses	62,847
Stockholders Equity	-24,419
Net Income	3,185
Comprehensive Net Income	3,185
Economic Capital Ratio	-55%